Physician profile
Taylor L Mader
NPI 1871888487
$11,548.60
in general payments reported to CMS, 2019-2025
29 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,998 · 2020: $777 · 2021: $1,409 · 2022: $1,831 · 2023: $1,821 · 2024: $1,989 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,461 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,460.89 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,117.88 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,543.75 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $1,301.20 | 2020-2025 | |
| Janssen Biotech, INC. | $1,297.54 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,223.81 | 2019-2025 | |
| Lilly USA, LLC | $1,222.73 | 2019-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $1,134.09 | 2019-2025 | |
| Organon LLC | $203.24 | 2022-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $179.46 | 2022-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $168.71 | 2019-2024 | Orencia |
| Regeneron Healthcare Solutions, INC. | $147.00 | 2019-2020 | |
| Genzyme Corporation | $131.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $111.35 | 2021-2024 | Saphnelo |
| Genentech USA, INC. | $111.18 | 2019-2025 | Gazyva, Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.12 | 2019-2023 | Cyltezo, Ofev |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $69.65 | 2022-2025 | Lupkynis |
| Sobi, INC | $66.94 | 2023-2024 | |
| Celgene Corporation | $65.69 | 2019-2024 | Orencia |
| Mallinckrodt Hospital Products INC. | $59.18 | 2025 | Acthar |
| Sandoz INC. | $56.46 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $43.12 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $42.39 | 2022-2025 | Strensiq |
| Radius Health, INC. | $37.05 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $25.30 | 2023-2024 | Opsumit, Uptravi |
| Scilex Pharmaceuticals INC. | $22.91 | 2025 | |
| Abbott Laboratories | $20.09 | 2023 | Octrode |
| Horizon Therapeutics Plc | $15.63 | 2019 | |
| Antares Pharma, INC. | $14.72 | 2019 | |
| Medtronic, INC. | $13.80 | 2025 | Vanta Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Mader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.